However, it is important to note that VEGF inhibition may potentially induce systemic adverse effects that could be serious, especially for patients with diabetes or the elderly (including patients with nAMD) who are at an increased risk for cardiovascular (CV) adverse events (AEs).6, 7. The gene discussed is VEGFA; the disease is diabetes mellitus.